Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.39 |
| ▸ | WNT3A | P56704 | 6/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31452888 | 0.86 | CLK1 (0.40) | CLK1DYRK1ADYRK1BCTNNB1WNT3A | |
| SCHEMBL14405286 | 0.77 | CTNNB1 (0.41) | CLK1DYRK1ADYRK1BCTNNB1WNT3A | |
| SCHEMBL30762291 | 0.77 | CTNNB1 (0.41) | CLK1DYRK1ADYRK1BCTNNB1WNT3A | |
| SCHEMBL29141427 | 0.77 | CTNNB1 (0.41) | CLK1DYRK1ADYRK1BCTNNB1WNT3A | |
| SCHEMBL18946020 | 0.77 | CTNNB1 (0.41) | CLK1DYRK1ADYRK1BCTNNB1WNT3A | |
| SCHEMBL12333251 | 0.77 | ADCY6 (0.42) | CLK1DYRK1ADYRK1BCTNNB1WNT3A | |
| SCHEMBL984492 | 0.76 | PRKCI (0.48) | DYRK1ADYRK1BPRKCISMN1; SMN2MAPT | |
| SCHEMBL7082445 | 0.76 | DRD2 (0.45) | CLK1DYRK1ADYRK1BMTNR1APRKCI | |
| SCHEMBL15290407 | 0.76 | DRD2 (0.45) | CLK1DYRK1ADYRK1BMTNR1APRKCI | |
| SCHEMBL27382541 | 0.76 | ITGB2 (0.53) | ITGB2ICAM1ITGALLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1139584-C | Heterocyclic compounds, method for preparing and medicine compositions containing same | ɪά��ʵ���� | 2004-02-25 | — | — | CN | claimed |
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | claimed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | claimed |
| CN-1260789-A | Heterocyclic compounds, method for preparing and medicine compositions containing same | ADIR CO (FR) | 2000-07-19 | — | — | CN | claimed |
| CN-1139584-C | Heterocyclic compounds, method for preparing and medicine compositions containing same | ɪά��ʵ���� | 2004-02-25 | — | — | CN | disclosed |
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | disclosed |
| US-6313160-B1 | FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-06 | — | — | US | disclosed |
| CN-1260789-A | Heterocyclic compounds, method for preparing and medicine compositions containing same | ADIR CO (FR) | 2000-07-19 | — | — | CN | disclosed |
| EP-0998471-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998052935-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052400-A1 | Substituted heterocyclic compounds | MTNR1A, MTNR1B, CBR1 | CLK1 4634/4885DYRK1A 3679/4885DYRK1B 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.